FDA label db3c178f-a6ec-412b-bcb9-e0bf3aed18c1

5.4 Arousability Some patients receiving Dexmedetomidine Hydrochloride Injection have been observed to be arousable and alert when stimulated. This alone should not be considered as evidence of lack of efficacy in the absence of other clinical signs and symptoms.

5.5 Withdrawal Procedural Sedation In adult subjects, withdrawal symptoms were not seen after discontinuation of short-term infusions of Dexmedetomidine Hydrochloride Injection (< 6 hours).

5.6 Tolerance and Tachyphylaxis Use of dexmedetomidine beyond 24 hours has been associated with tolerance and tachyphylaxis and a dose-related increase in adverse reactions [see Adverse Reactions (6.1) ] .

5.7 Hepatic Impairment Since Dexmedetomidine Hydrochloride Injection clearance decreases with severity of hepatic impairment, dose reduction should be considered in patients with impaired hepatic function [see Dosage and Administration (2.2) ] .

6 ADVERSE REACTIONS The most common adverse reactions (incidence greater than 2%) are hypotension, bradycardia, and dry mouth. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. Use of Dexmedetomidine Hydrochloride Injection has been associated with the following serious adverse reactions: Hypotension, bradycardia and sinus arrest [see Warnings and Precautions (5.2) ] Transient hypertension [see Warnings and Precautions (5.3) ] Most common treatment-emergent adverse reactions, occurring in greater than 2% of patients in procedural sedation studies include hypotension, bradycardia and dry mouth. Procedural Sedation Adverse reaction information is derived from the two trials for procedural sedation [see Clinical Studies (14.1) ] in which 318 adult patients received Dexmedetomidine Hydrochloride Injection. The mean total dose was 1.6 mcg/kg (range: 0.5 to 6.7), mean dose per hour was 1.3 mcg/kg/hr (range: 0.3 to 6.1) and the mean duration of infusion of 1.5 hours (range: 0.1 to 6.2). The population was between 18 to 93 years of age, ASA I-IV, 30% ≥ 65 years of age, 52% male and 61% Caucasian. Treatment-emergent adverse reactions occurring at an incidence of > 2% are provided in Table 2. The most frequent adverse reactions were hypotension, bradycardia, and dry mouth [see Warnings and Precautions (5.2) ] . Pre-specified criteria for the vital signs to be reported as adverse reactions are footnoted below the table. The decrease in respiratory rate and hypoxia was similar between Dexmedetomidine Hydrochloride Injection and comparator groups in both studies. Table 2: Adverse Reactions with an Incidence > 2% — Procedural Sedation Population Adverse Event Dexmedetomidine Hydrochloride Injection (N = 318) (%) Placebo (N = 113) (%) Hypotension 1 Respiratory Depression 2 Bradycardia 3 Hypertension 4 Tachycardia 5 Nausea Dry Mouth Hypoxia 6 Bradypnea 54% 37% 14% 13% 5% 3% 3% 2% 2% 30% 32% 4% 24% 17% 2% 1% 3% 4% 1 Hypotension was defined in absolute and relative terms as Systolic blood pressure of < 80 mmHg or ≤ 30% lower than pre-study drug infusion value, or Diastolic blood pressure of < 50 mmHg. 2 Respiratory depression was defined in absolute and relative terms as respiratory rate (RR) < 8 beats per minute or > 25% decrease from baseline. 3 Bradycardia was defined in absolute and relative terms as < 40 beats per minute or ≤ 30% lower than pre-study drug infusion value. 4 Hypertension was defined in absolute and relative terms as Systolic blood pressure > 180 mmHg or ≥ 30% higher than pre-study drug infusion value or Diastolic blood pressure of > 100 mmHg. 5 Tachycardia was defined in absolute and relative terms as > 120 beats per minute or ≥ 30% greater than pre-study drug infusion value. 6 Hypoxia was defined in absolute and relative terms as SpO 2 < 90% or 10% decrease from baseline. 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of Dexmedetomidine Hydrochloride Injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Hypotension and bradycardia were the most common adverse reactions associated with the use of Dexmedetomidine Hydrochloride Injection during post approval use of the drug. Table 3: Adverse Reactions Experienced During Post-approval Use of Dexmedetomidine Hydrochloride Injection System Organ Class Preferred Term Blood and Lymphatic System Disorders Anemia Cardiac Disorders Arrhythmia, atrial fibrillation, atrioventricular block, bradycardia, cardiac arrest, cardiac disorder, extrasystoles, myocardial infarction, supraventricular tachycardia, tachycardia, ventricular arrhythmia, ventricular tachycardia Eye Disorders Photopsia, visual impairment Gastrointestinal Disorders Abdominal pain, diarrhea, nausea, vomiting General Disorders and Administration Site Conditions Chills, hyperpyrexia, pain, pyrexia, thirst Hepatobiliary Disorders Hepatic function abnormal, hyperbilirubinemia Investigations Alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood urea increased, electrocardiogram T wave inversion, gamma-glutamyl transferase increased, electrocardiogram QT prolonged Metabolism and Nutrition Disorders Acidosis, hyperkalemia, hypoglycemia, hypovolemia, hypernatremia Nervous System Disorders Convulsion, dizziness, headache, neuralgia, neuritis, speech disorder Psychiatric Disorders Agitation, confusional state, delirium, hallucination, illusion Renal and Urinary Disorders Oliguria, polyuria Respiratory, Thoracic and Mediastinal Disorders Apnea, bronchospasm, dyspnea, hypercapnia, hypoventilation, hypoxia, pulmonary congestion, respiratory acidosis Skin and Subcutaneous Tissue Disorders Hyperhidrosis Surgical and Medical Procedures Light anesthesia Vascular Disorders Blood pressure fluctuation, hemorrhage, hypertension, hypotension

6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. Use of Dexmedetomidine Hydrochloride Injection has been associated with the following serious adverse reactions: Hypotension, bradycardia and sinus arrest [see Warnings and Precautions (5.2) ] Transient hypertension [see Warnings and Precautions (5.3) ] Most common treatment-emergent adverse reactions, occurring in greater than 2% of patients in procedural sedation studies include hypotension, bradycardia and dry mouth. Procedural Sedation Adverse reaction information is derived from the two trials for procedural sedation [see Clinical Studies (14.1) ] in which 318 adult patients received Dexmedetomidine Hydrochloride Injection. The mean total dose was 1.6 mcg/kg (range: 0.5 to 6.7), mean dose per hour was 1.3 mcg/kg/hr (range: 0.3 to 6.1) and the mean duration of infusion of 1.5 hours (range: 0.1 to 6.2). The population was between 18 to 93 years of age, ASA I-IV, 30% ≥ 65 years of age, 52% male and 61% Caucasian. Treatment-emergent adverse reactions occurring at an incidence of > 2% are provided in Table 2. The most frequent adverse reactions were hypotension, bradycardia, and dry mouth [see Warnings and Precautions (5.2) ] . Pre-specified criteria for the vital signs to be reported as adverse reactions are footnoted below the table. The decrease in respiratory rate and hypoxia was similar between Dexmedetomidine Hydrochloride Injection and comparator groups in both studies. Table 2: Adverse Reactions with an Incidence > 2% — Procedural Sedation Population Adverse Event Dexmedetomidine Hydrochloride Injection (N = 318) (%) Placebo (N = 113) (%) Hypotension 1 Respiratory Depression 2 Bradycardia 3 Hypertension 4 Tachycardia 5 Nausea Dry Mouth Hypoxia 6 Bradypnea 54% 37% 14% 13% 5% 3% 3% 2% 2% 30% 32% 4% 24% 17% 2% 1% 3% 4% 1 Hypotension was defined in absolute and relative terms as Systolic blood pressure of < 80 mmHg or ≤ 30% lower than pre-study drug infusion value, or Diastolic blood pressure of < 50 mmHg. 2 Respiratory depression was defined in absolute and relative terms as respiratory rate (RR) < 8 beats per minute or > 25% decrease from baseline. 3 Bradycardia was defined in absolute and relative terms as < 40 beats per minute or ≤ 30% lower than pre-study drug infusion value. 4 Hypertension was defined in absolute and relative terms as Systolic blood pressure > 180 mmHg or ≥ 30% higher than pre-study drug infusion value or Diastolic blood pressure of > 100 mmHg. 5 Tachycardia was defined in absolute and relative terms as > 120 beats per minute or ≥ 30% greater than pre-study drug infusion value. 6 Hypoxia was defined in absolute and relative terms as SpO 2 < 90% or 10% decrease from baseline.

6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of Dexmedetomidine Hydrochloride Injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Hypotension and bradycardia were the most common adverse reactions associated with the use of Dexmedetomidine Hydrochloride Injection during post approval use of the drug. Table 3: Adverse Reactions Experienced During Post-approval Use of Dexmedetomidine Hydrochloride Injection System Organ Class Preferred Term Blood and Lymphatic System Disorders Anemia Cardiac Disorders Arrhythmia, atrial fibrillation, atrioventricular block, bradycardia, cardiac arrest, cardiac disorder, extrasystoles, myocardial infarction, supraventricular tachycardia, tachycardia, ventricular arrhythmia, ventricular tachycardia Eye Disorders Photopsia, visual impairment Gastrointestinal Disorders Abdominal pain, diarrhea, nausea, vomiting General Disorders and Administration Site Conditions Chills, hyperpyrexia, pain, pyrexia, thirst Hepatobiliary Disorders Hepatic function abnormal, hyperbilirubinemia Investigations Alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood urea increased, electrocardiogram T wave inversion, gamma-glutamyl transferase increased, electrocardiogram QT prolonged Metabolism and Nutrition Disorders Acidosis, hyperkalemia, hypoglycemia, hypovolemia, hypernatremia Nervous System Disorders Convulsion, dizziness, headache, neuralgia, neuritis, speech disorder Psychiatric Disorders Agitation, confusional state, delirium, hallucination, illusion Renal and Urinary Disorders Oliguria, polyuria Respiratory, Thoracic and Mediastinal Disorders Apnea, bronchospasm, dyspnea, hypercapnia, hypoventilation, hypoxia, pulmonary congestion, respiratory acidosis Skin and Subcutaneous Tissue Disorders Hyperhidrosis Surgical and Medical Procedures Light anesthesia Vascular Disorders Blood pressure fluctuation, hemorrhage, hypertension, hypotension

<table cellspacing="0" cellpadding="0" border="0"> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left" valign="bottom"> <content styleCode="bold"> Adverse Event</content> </td> <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">Dexmedetomidine Hydrochloride Injection</content> <content styleCode="bold"> </content> <content styleCode="bold">(N = 318)</content> (%) </td> <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">Placebo</content> <content styleCode="bold">(N = 113)</content> (%) </td> </tr> <tr> <td styleCode="Lrule Rrule" align="left" valign="middle">Hypotension¹ Respiratory Depression² Bradycardia³ Hypertension⁴ Tachycardia⁵ Nausea Dry Mouth Hypoxia⁶ Bradypnea </td> <td styleCode="Rrule" align="center" valign="middle">54% 37% 14% 13% 5% 3% 3% 2% 2% </td> <td styleCode="Rrule" align="center" valign="middle">30% 32% 4% 24% 17% 2% 1% 3% 4% </td> </tr> </tbody> </table>